COMPARISON OF POST-SURGICAL PAIN RELIEF RESULTS FOR BASIC CELL CANCER USING FENTANYL PCA VERSUS INTRAVENOUS PARACETAMOL
Main Article Content
Abstract
Objective: To compare the results of postoperative pain relief after basal cell carcinoma surgery using Fentanyl PCA versus intravenous Paracetamol at the National Hospital of Dermatology and Venereology in 2023.
Subjects and methods: This was a cross-sectional descriptive study on 40 patients who underwent surgery for basal cell carcinoma at the National Hospital of Dermatology and Venereology from March to October 2023. The 40 patients were divided into two equal groups: one group received Fentanyl PCA, and the other group received intravenous Paracetamol.
Results: Postoperatively, the mean VAS score for both groups was 5.8-5.9 points. For the Fentanyl PCA group, the postoperative VAS scores at 6 hours, 12 hours, 24 hours, and 72 hours were 4.05 ± 0.39; 2.95 ± 0.39; 2.35 ± 0.49; and 1.05 ± 0.22, respectively. For the intravenous Paracetamol group, the postoperative VAS scores at 6 hours, 12 hours, 24 hours, and 72 hours were 5.70 ± 0.57; 4.15 ± 0.49; 3.75 ± 0.55; and 1.90 ± 0.45, respectively. At discharge, both groups were pain-free with a VAS score < 1 point. Adverse effects were higher in the Fentanyl PCA group (25%) than in the intravenous Paracetamol group (15%) with p > 0.05.
Conclusion: Fentanyl PCA pain relief compared to intravenous Paracetamol pain relief showed superiority in the first 72 hours after surgery. Pain levels during movement were lower in the Fentanyl PCA group than in the intravenous Paracetamol group (p < 0.05). At the time of discharge, pain levels during movement in the intravenous Paracetamol group had decreased significantly, comparable to the Fentanyl PCA group. Adverse effects in both groups were not statistically different (p > 0.05).
Article Details
Keywords
Pain relief, Fentanyl, PCA, basal cell.
References
[2] Telfer N.R, Colver G.B, Bowers P.W. Guidelines for the management of basal cell carcinoma. Br J Dermatol, 2008, 159 (1): 35-48. doi: 10.1111/j.1365-2133.2008.08666.x.
[3] Kim J.Y, Kozlow J.H et al. Guidelines of care for the management of basal cell carcinoma. J Am Acad Dermatol, 2018, 78 (3): 540-59. doi: 10.1016/j.jaad.2017.10.006.
[4] Correll D.J, Vlassakov K.V, Kissin I. No evidence of real progress in treatment of acute pain, 1993-2012: scientometric analysis. J Pain Res, 2014, 7: 199-210. doi: 10.2147/JPR.S60842.
[5] Roewert-Huber J, Lange-Asschenfeldt B et al. Epidemiology and aetiology of basal cell carcinoma. Br J Dermatol, 2007, 157 (Suppl 2): 47-51. doi: 10.1111/j.1365-2133.2007.08273.x
[6] Aubrun F, Valade N et al. Predictive factors of severe postoperative pain in the postanesthesia care unit. Anesth Analg, 2008, 106 (5): 1535-1541. doi: 10.1213/ane.0b013e318168b2ce
[7] McNicol E.D, Ferguson M.C, Hudcova J. Patient controlled Opioid analgesia versus non-patient controlled Opioid analgesia for postoperative pain. Cochrane Database Syst Rev, 2015 (6): CD003348. doi: 10.1002/14651858.CD003348.pub3
[8] Ballantyne J.C, Carr D.B et al. Postoperative patient-controlled analgesia: meta-analyses of initial randomized control trials. J Clin Anesth, 1993, 5 (3): 182-193. doi: 10.1016/0952-8180(93)90013-5
[9] Kehlet H, Wilmore D.W. Evidence-based surgical care and the evolution of fast-track surgery. Ann Surg, 2008, 248 (2): 189-198. doi: 10.1097/SLA.0b013e31817f2c1a
[10] Breivik H, Stubhaug A. Management of acute postoperative pain: still a long way to go! Pain, 2008, 137 (2): 233-234. doi: 10.1016/j.pain.2008.04.014
[11] Gan T.J, Diemunsch P, Habib A.S et al. Consensus guidelines for the management of postoperative nausea and vomiting. Anesth Analg, 2014,118 (1): 85-113. doi: 10.1213/ANE.0000000000000002